BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, April 28, 2014
At least 18 biotechs and pharmas reported earnings
last week. Gilead Sciences Inc. (NASDAQ:GILD) added nearly $6 billion to
its market cap last week, while fellow big biotech Amgen Inc. (NASDAQ:AMGN)
lost more than $3 billion. Gilead blew away the Street's EPS and revenue
estimates as the first full quarter of Sovaldi sofosbuvir sales came in at $2.3
billion. According to Deutsche Bank's Robyn Karnauskas, the Street expected $1
billion in sales for the HCV drug, which Gilead launched last December. Amgen
missed analyst consensus EPS and revenue estimates partly due to
lower-than-expected sales of autoimmune drug Enbrel etanercept.
AstraZeneca plc (LSE:AZN; NYSE:AZN) ended the
week up 8%, tacking on $6.5 billion in market value. AZ shares gained 9% last
Monday following media reports that the pharma was previously in talks to be
acquired by Pfizer Inc. (NYSE:PFE). According to the reports, the
pharmas are no longer in negotiations. AZN reported 1Q14 EPS on Thursday that
missed the Street's EPS estimate.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]